C4 Therapeutics Secures $20M Upfront, $1B+ Milestones in Expanded Roche Partnership for Cancer Drug Development
CCCC has more than doubled off its 52-week low of $1.085.
Summary
C4 Therapeutics announced a new collaboration agreement with Roche, expanding their long-term partnership to discover and develop degrader-antibody conjugates (DACs) for oncology targets. C4T will receive a significant $20 million upfront payment and is eligible for over $1 billion in potential discovery, development, and commercial milestones, plus tiered royalties. This substantial non-dilutive funding, particularly the upfront payment representing approximately 7% of C4T's market cap, significantly strengthens the company's financial position and validates its proprietary TORPEDO® platform. This agreement builds on the company's successful $116.9 million offering in late 2025, further extending its cash runway and de-risking its pipeline. Traders will be watching for progress in the DAC programs and the achievement of initial milestones.
At the time of this announcement, CCCC was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $283M. The 52-week trading range was $1.09 to $3.82. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.